wegovy fda - Search News

Order byBest matchMost fresh

News

Novo, Wegovy and fatty liver disease

FDA Approves Wegovy to Treat Serious Liver Disease

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S. adults — or roughly 6% of the population — have the condition, according to the FDA.

Continue reading

BioPharma Dive · 2d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Fierce Pharma · 2d

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Endocrinology Advisor2d

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

2don MSN

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk’s breakup with Hims

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results